What is it about?
This book chapter explores the growing evidence supporting Calpain 2 protease as a critical player in the progression and metastasis of breast cancer. It reviews the molecular functions of Calpain 2 in regulating cell migration, invasion, apoptosis, and tumor microenvironment remodeling, highlighting its involvement in aggressive cancer phenotypes. The chapter also discusses preclinical studies evaluating Calpain 2 inhibitors, their therapeutic potential, and challenges in translating these findings into clinical applications. By integrating current knowledge, it positions Calpain 2 as a promising biomarker and novel target for future breast cancer therapies.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Breast cancer remains a leading cause of cancer-related mortality among women, and there is a critical need for new therapeutic targets to improve outcomes, especially in aggressive and treatment-resistant cases. This chapter is important because it sheds light on Calpain 2 protease as a key regulator of tumor progression and metastasis, offering a novel avenue for targeted intervention. By summarizing current research and therapeutic prospects, it provides a foundation for future studies aimed at developing Calpain 2-based strategies to enhance breast cancer treatment.
Perspectives
The chapter highlights Calpain 2 as a promising molecular target for developing innovative breast cancer therapies. It emphasizes the potential of Calpain 2 inhibition to reduce tumor invasion and metastasis in aggressive breast cancer subtypes. It underscores the need for translating Calpain 2 research into clinical applications to improve patient outcomes.
Dr.Ramakrishnan Veerabathiran
Chettinad Health City
Read the Original
This page is a summary of: The Emerging Role of Calpain 2 Protease as a Therapeutic Target in Breast Cancer, October 2024, Taylor & Francis,
DOI: 10.1201/9781003394693-17.
You can read the full text:
Contributors
The following have contributed to this page







